Business
Entia Biosciences, Inc. (OTCQB: ERGO) to Present Results of Chronic Kidney Disease Medical Food Clinical Study at American Society of Nephrology / Kidney Week 2016 Annual Meeting
Entia Biosciences, Inc. (OTCQB: ERGO) to Present Results of Chronic Kidney Disease Medical Food Clinical Study at American Society of Nephrology / Kidney Week 2016 Annual Meeting.
About this update from Entia Biosciences Inc
[{"type":"text","content":"\n\n PORTLAND, Ore., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) was informed by the American Society of Nephrology (“ASN”) that its submission of “late breaking clinical trials” results has been accepted for presentation at the ASN Kidney Week 2016 Annual Meeting November 17-20 in Chicago, at the McCormick Place Convention Center.  The presentation is titled: “ErgoD2 Medical Food Therapy: A Novel Strategy to Delay Progression of Chronic Kidney Disease (CKD).”\n “The acceptance of our CKD clinical trial study for presentation is evidence of the Society’s interest in the potential of our technology,” stated Marvin S. Hausman MD, Entia Chief Science and Technology Officer.  It is indeed an honor for our Company and we are looking forward to showing a large audience of nephrologists from the United States and the world the therapeutic value of adding our ErgoD2® medical food to the CKD patient standard of care that is currently available.” Chronic Kidney Disease takes a significant toll on the health of more than 25 million individuals in the U.S. alone.  Progression of the disease leads to dialysis, and eventually the need for a kidney transplant.  The cost to the U.S. Healthcare system was reported as $42.5 billion in 2009 by the National Institutes of Health, and has been growing at a compound rate of +9.8% annually. The product being tested is a specific proprietary blend of Entia’s patented ErgoD2 technology.  Entia Biosciences is the first company to develop, produce and market consumer products with all-natural formulas for the amino acid L-ergothioneine and enhanced vitamin D2.   This novel medical food is a supplement to a patient’s existing prescribed regimen of care and is intended to increase kidney filtration rates, improve iron levels and increase production of red blood cells.  If the study proves successful, Entia’s ErgoD2 product formulation for Chronic Kidney Disease will provide patients with the first all-natural, organic medical food product designed to improve the health and well-being of the patient, enhance the dietary management of the disease and potentially slow its progression. The application of medical foods containing ErgoD2 formulations is not limited t...